ClinicalTrials.gg
Active, not recruitingNCT05953389Updated Oct 2, 2025

Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents

A Phase 2 interventional study of Pitolisant and Placebo in Autism Spectrum Disorder, sponsored by Bioprojet. Active, not recruiting at 15 sites in 4 countries. Open to male participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Bioprojet · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as active, not recruiting.
Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
Male
01

Study summary

Proof of concept, multicenter, randomized, double-blind, placebo-controlled, parallel-group, study to investigate the effect, safety, tolerability and pharmacokinetics of pitolisant in male children and adolescents with Autism Spectrum Disorders.

Read the detailed description

First clinical study to assess the effect of BF2.649 in male children and adolescent with a diagnosis of Autism spectrum disorders according to DSM-5 criteria and confirmed by the Autism Diagnostic Observation Schedule (ADOS-2) or Autism Diagnostic Interview-Revised (ADI-R) over a 12-weeks period.

02

Conditions studied

  • Autism Spectrum Disorder
03

In context

Autism Spectrum Disorder

1,724 studies on the registry are indexed under Autism Spectrum Disorder; 500 are open to participants now.

This study's planned enrollment of 62 is above the median of 52 across 1,368 interventional studies indexed under Autism Spectrum Disorder.

Browse Autism Spectrum Disorder studies →

Lead sponsor

Bioprojet is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants and their parent(s)/legal guardian(s) are willing and able to give informed assent and consent for participation in the study.
  • Male children and adolescents aged from 6 to 17 inclusive for the duration of study participation.
  • Diagnosis of autism spectrum disorders (ASD) as per the (DSM-5) criteria confirmed by the Autism Diagnostic Observation Schedule (ADOS-2) or the Autism Diagnostic Interview-Revised (ADI-R).
  • Intelligence Quotient (IQ) ≥ 70 using Wechsler Intelligence Scale.
  • Social Responsiveness Scale Second Edition (SRS-2) total T-score ≥ 66 at screening and baseline.

Exclusion criteria

Exclusion Criteria:

  • Previous genetic diagnosis of ASD-known "syndromic" ASD (e.g., Fragile X syndrome, Angelman syndrome, Prader-Willi, Rett's syndrome, tuberous sclerosis, Dup15q syndrome).
  • History of suicidal behavior or suicidal ideation in the past 12 months, or a positive answer to questions 4 or 5 on the Columbia-Suicide-Severity Rating Scale (C-SSRS) at screening and/or baseline, and/or is a significant risk for suicidal behavior per investigator judgement.
  • History or current diagnosis of epilepsy or any seizure occurring after the age of 5.
  • deviation from normal on 12-lead that results in an active medical problem, per investigator judgement or, with a interval by Fridericia (QTcF) > 450ms at screening.
  • Severe hepatic impairment ( C) or with any other hepatic significant abnormality in the physical examination or (ALAT) or aspartate aminotransferase (ASAT) ≥ 2x (ULN) for age at laboratory results.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Pitolisant

    One tablet of pitolisant 5 mg, two tablets of pitolisant 5 mg, one tablet of pitolisant 20 mg or two tablets of pitolisant 20 mg per day for 12 weeks.

    Drug: Pitolisant

  • Placebo comparator
    Placebo

    One or two tablets of matching placebo per day for 12 weeks.

    Drug: Placebo

Interventions

  • histamine H3 receptor antagonist/inverse agonist

    Also known as: BF2.649

  • DrugPlacebo

    Matching placebo of pitolisant tablets

06

What researchers measure

Primary outcomes

  1. Social Responsiveness Scale Second Edition (SRS-2) total score

    65-item informant-based rating scale designed specifically for use in Autism Spectrum Disorders to quantitatively measure an individual's ability to engage in emotionally appropriate reciprocal social behavior with higher scores indicating greater impairment.

    Time frame: 12 weeks

Secondary outcomes

  1. Vineland Adaptive Behavior Scale III (VABS III) total score

    Instrument that measures socialization, communication, daily living skills, motor skills and maladaptive behavior of individuals with intellectual disabilities;

    Time frame: 12 weeks

  2. Incidence of Treatment-Emergent adverse events (AEs) as assessed by AEs collection

    Safety assessment of pitolisant based on adverse events (AEs) reporting during the treatment pe

    Time frame: 12 weeks

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Oct 2025, 22 months after the start.

Of 67 non-industry phase 2 interventional studies under Autism Spectrum Disorder, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 63. This study's planned 22 months is below that.

Counting every sponsor, half of 82 studies reached it within 36 months; a quarter within 23 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2023
First posted
Jul 20, 2023
StartActual
Dec 20, 2023
Primary completionEst.
Oct 2025
CompletionEst.
Nov 2025
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05953389
Lead sponsor
Bioprojet
Responsible party
Sponsor
First posted
Jul 20, 2023
Start date
Dec 20, 2023
Primary completion
Oct 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Oct 2, 2025

Study contacts

Olivier Bonnot, MD, Prof.
principal investigator · Etablissement Public de Santé Barthélemy Durand, Sainte-Geneviève-des-Bois, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitolisant

Start the discussion